{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:39:57Z","timestamp":1777592397046,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003010","name":"Ege \u00dcniversitesi","doi-asserted-by":"publisher","award":["2015-TIP-063"],"award-info":[{"award-number":["2015-TIP-063"]}],"id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003010","name":"Ege \u00dcniversitesi","doi-asserted-by":"publisher","award":["15-TIP-019"],"award-info":[{"award-number":["15-TIP-019"]}],"id":[{"id":"10.13039\/501100003010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ejphar.2021.174446","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T10:44:28Z","timestamp":1630061068000},"page":"174446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["PI3K\/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia"],"prefix":"10.1016","volume":"910","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6797-7655","authenticated-orcid":false,"given":"Cagla","family":"Kayabasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0659-1097","authenticated-orcid":false,"given":"Besra Ozmen","family":"Yelken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-4175","authenticated-orcid":false,"given":"Aycan","family":"Asik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugce Balci","family":"Okcanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Sogutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6760-8921","authenticated-orcid":false,"given":"Roya","family":"Gasimli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunde Yilmaz","family":"Susluer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guray","family":"Saydam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cigir Biray","family":"Avci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cumhur","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejphar.2021.174446_bib1","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/cncr.22699","article-title":"Characterization of ph-negative abnormal clones emerging during imatinib therapy","volume":"109","author":"Abruzzese","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2021.174446_bib2","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1038\/cddis.2013.309","article-title":"Pi3k\/mtor pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor","volume":"4","author":"Airiau","year":"2013","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.ejphar.2021.174446_bib3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part i: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.ejphar.2021.174446_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on mapk: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ejphar.2021.174446_bib5","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of cml blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ejphar.2021.174446_bib6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1101\/gad.14.15.1920","article-title":"Translational control of c\/ebpalpha and c\/ebpbeta isoform expression","volume":"14","author":"Calkhoven","year":"2000","journal-title":"Genes Dev."},{"issue":"40","key":"10.1016\/j.ejphar.2021.174446_bib7","doi-asserted-by":"crossref","first-page":"66287","DOI":"10.18632\/oncotarget.11507","article-title":"The bcr-abl\/nf-kappab signal transduction network: a long lasting relationship in philadelphia positive leukemias","volume":"7","author":"Carra","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ejphar.2021.174446_bib8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of pi3k\/akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ejphar.2021.174446_bib9","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.3892\/or.2016.5176","article-title":"Idelalisib induces g1 arrest and apoptosis in chronic myeloid leukemia k562 cells","volume":"36","author":"Chen","year":"2016","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174446_bib10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Canc. Res."},{"issue":"4","key":"10.1016\/j.ejphar.2021.174446_bib11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: bcr-abl","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin. Canc. Res."},{"issue":"11","key":"10.1016\/j.ejphar.2021.174446_bib12","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (bms-354825) targets an earlier progenitor population than imatinib in primary cml but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ejphar.2021.174446_bib13","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood.V124.21.3135.3135","article-title":"Long-term follow-up of ponatinib efficacy and safety in the phase 2 pace trial","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejphar.2021.174446_bib14","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2003-02-0479","article-title":"The amino terminal and e2f interaction domains are critical for c\/ebp alpha-mediated induction of granulopoietic development of hematopoietic cells","volume":"102","author":"D'Alo","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejphar.2021.174446_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.18388\/abp.2013_2014","article-title":"Role of anti-apoptotic pathways activated by bcr\/abl in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors","volume":"60","author":"Danisz","year":"2013","journal-title":"Acta Biochim. Pol."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174446_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174446_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to sti571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejphar.2021.174446_bib18","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3324\/haematol.2017.167080","article-title":"Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib","volume":"102","author":"Gullaksen","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ejphar.2021.174446_bib19","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on bcr-abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2021.174446_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1749-6632.2003.tb03242.x","article-title":"Biology and plasticity of cd133+ hematopoietic stem cells","volume":"996","author":"Handgretinger","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174446_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1535-7163.MCT-12-0466","article-title":"Vs-5584, a novel and highly selective pi3k\/mtor kinase inhibitor for the treatment of cancer","volume":"12","author":"Hart","year":"2013","journal-title":"Mol. Canc. Therapeut."},{"issue":"9","key":"10.1016\/j.ejphar.2021.174446_bib22","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.ejphar.2021.174446_bib23","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/MCB.21.11.3789-3806.2001","article-title":"C-myc is a critical target for c\/ebpalpha in granulopoiesis","volume":"21","author":"Johansen","year":"2001","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejphar.2021.174446_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1079-9796(03)00070-6","article-title":"Involvement of akt kinase in the action of sti571 on chronic myelogenous leukemia cells","volume":"31","author":"Kawauchi","year":"2003","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ejphar.2021.174446_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.gene.2017.09.036","article-title":"Comparative effect of imatinib and ponatinib on autophagy and mirnome in chronic myeloid leukemia","volume":"637","author":"Kayabasi","year":"2017","journal-title":"Gene"},{"issue":"38","key":"10.1016\/j.ejphar.2021.174446_bib26","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1038\/sj.onc.1205724","article-title":"Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of sti571","volume":"21","author":"Klejman","year":"2002","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ejphar.2021.174446_bib27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/0008-5472.CAN-14-1223","article-title":"Pi3k\/mtor dual inhibitor vs-5584 preferentially targets cancer stem cells","volume":"75","author":"Kolev","year":"2015","journal-title":"Canc. Res."},{"issue":"10","key":"10.1016\/j.ejphar.2021.174446_bib28","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nm1489","article-title":"Requirement for cd44 in homing and engraftment of bcr-abl-expressing leukemic stem cells","volume":"12","author":"Krause","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2021.174446_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fonc.2013.00108","article-title":"Targeting pi3k in cancer: any good news?","volume":"3","author":"Martini","year":"2013","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.ejphar.2021.174446_bib30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/35085068","article-title":"Transcriptional regulation by the phosphorylation-dependent factor creb","volume":"2","author":"Mayr","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2021.174446_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/asheducation-2008.1.427","article-title":"Novel agents in cml therapy: tyrosine kinase inhibitors and beyond","author":"Melo","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.ejphar.2021.174446_bib32","first-page":"897","article-title":"Granulocyte colony-stimulating factor regulates myeloid differentiation through ccaat\/enhancer-binding protein epsilon","volume":"98","author":"Nakajima","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ejphar.2021.174446_bib33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"Ap24534, a pan-bcr-abl inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Canc. Cell"},{"issue":"2","key":"10.1016\/j.ejphar.2021.174446_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/cbt.26725","article-title":"Efficacy of the dual pi3k and mtor inhibitor nvp-bez235 in combination with nilotinib against bcr-abl-positive leukemia cells involves the abl kinase domain mutation","volume":"15","author":"Okabe","year":"2014","journal-title":"Canc. Biol. Ther."},{"issue":"33","key":"10.1016\/j.ejphar.2021.174446_bib35","doi-asserted-by":"crossref","first-page":"53116","DOI":"10.18632\/oncotarget.10605","article-title":"Combination therapy with copanlisib and abl tyrosine kinase inhibitors against philadelphia chromosome-positive resistant cells","volume":"7","author":"Okabe","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ejphar.2021.174446_bib36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2174\/1389450117666160615074120","article-title":"Cellular and molecular networks in chronic myeloid leukemia: the leukemic stem, progenitor and stromal cell interplay","volume":"18","author":"Perrotti","year":"2017","journal-title":"Curr. Drug Targets"},{"issue":"11","key":"10.1016\/j.ejphar.2021.174446_bib37","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/ci500493m","article-title":"Structure and ligand-based design of mtor and pi3-kinase inhibitors leading to the clinical candidates vs-5584 (sb2343) and sb2602","volume":"54","author":"Poulsen","year":"2014","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejphar.2021.174446_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"Bcr-abl1-independent pi3kinase activation causing imatinib-resistance","volume":"4","author":"Quentmeier","year":"2011","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.ejphar.2021.174446_bib39","first-page":"1163","article-title":"Further evidence for the existence of a clonal ph-negative stage in some cases of ph-positive chronic myelocytic leukemia","volume":"7","author":"Raskind","year":"1993","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejphar.2021.174446_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nri2024","article-title":"Transcription factors in myeloid development: balancing differentiation with transformation","volume":"7","author":"Rosenbauer","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174446_bib41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11899-011-0079-9","article-title":"New drugs for chronic myelogenous leukemia","volume":"6","author":"Santos","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"issue":"17","key":"10.1016\/j.ejphar.2021.174446_bib42","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2021.174446_bib43","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/blood-2002-01-0043","article-title":"The effects of bcr-abl on c\/ebp transcription-factor regulation and neutrophilic differentiation are reversed by the abl kinase inhibitor imatinib mesylate","volume":"101","author":"Schuster","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejphar.2021.174446_bib44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12185-009-0256-y","article-title":"Il-6-induced activation of myc is responsible for the down-regulation of cd33 expression in cd33+ myeloma cells","volume":"89","author":"Shamsasenjan","year":"2009","journal-title":"Int. J. Hematol."},{"issue":"16","key":"10.1016\/j.ejphar.2021.174446_bib45","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1128\/MCB.20.16.5986-5997.2000","article-title":"C\/ebpalpha inhibits cell growth via direct repression of e2f-dp-mediated transcription","volume":"20","author":"Slomiany","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2021.174446_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bcp.2017.11.022","article-title":"Targeting pi3k, mtor, erk, and bcl-2 signaling network shows superior antileukemic activity against aml ex vivo","volume":"148","author":"Su","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejphar.2021.174446_bib47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase akt pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Canc."},{"issue":"7","key":"10.1016\/j.ejphar.2021.174446_bib48","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0165-6147(03)00163-9","article-title":"Phosphoinositide 3-kinase signalling--which way to target?","volume":"24","author":"Wymann","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2021.174446_bib49","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2147\/DDDT.S132092","article-title":"Efficacy of the dual pi3k and mtor inhibitor nvp-bez235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines","volume":"11","author":"Xin","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2021.174446_bib50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"Bcr-abl1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Canc. Cell"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921006002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:26:18Z","timestamp":1777407978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921006002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":50,"alternative-id":["S0014299921006002"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174446","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K\/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174446"}}